 |
26 Diseases |  |
58 Trials |
|
58 Trials |  |
4692 News |  |
| «12...89101112131415161718...6263» |
- ||| Tivicay (dolutegravir) / ViiV Healthcare
Trial completion, Enrollment change: Dolatav: A Study of a Nucleoside Sparing Regimen in HIV-1 Infected Patients With Detectable Viremia (clinicaltrials.gov) - Sep 13, 2023
P2, N=10, Completed, Sponsor: Castagna Antonella
Unknown status --> Completed | N=40 --> 10
- | Tivicay (dolutegravir) / ViiV Healthcare
Journal: Alternative dolutegravir dosing strategies with concurrent rifapentine utilized for latent tuberculosis treatment. (Pubmed Central) - Sep 13, 2023
Unknown status --> Completed | N=40 --> 10 The patient had baseline suppressed HIV viral load on fixed dose combination dolutegravir/abacavir/lamivudine when once-weekly rifapentine 900
- Pifeltro (doravirine) / Merck (MSD), Tivicay (dolutegravir) / ViiV Healthcare
Doravirine plus dolutegravir two-drug regimen as a maintenance ART: results from a French cohort study (ETIUDA) - Sep 10, 2023 - Abstract #EACS2023EACS_315;
Discontinuations were mainly due to side effects. Rate and reason of discontinuation need to be compared to other dual strategies.
- Tivicay (dolutegravir) / ViiV Healthcare, GSK3640254 / ViiV Healthcare
Efficacy and Safety of the HIV-1 Maturation Inhibitor GSK3640254 + Dolutegravir as a 2-Drug Regimen in Treatment-Naive Adults: 24-Week Results From the Phase IIb DYNAMIC Study (ETIUDA) - Sep 10, 2023 - Abstract #EACS2023EACS_314;
Rate and reason of discontinuation need to be compared to other dual strategies. Method :
- GSK3640254 / ViiV Healthcare
Efficacy and Safety of the HIV-1 Maturation Inhibitor GSK3640254 + 2 NRTIs in Treatment-Naive Adults: 24-Week Results From the Phase IIb, Dose-Range Finding DOMINO Study (ETIUDA) - Sep 10, 2023 - Abstract #EACS2023EACS_313;
Method : Method :
- Rates and reasons for antiretroviral switches with implicated drug associations: a post-COVID 10-year comparison (ETIUDA) - Sep 10, 2023 - Abstract #EACS2023EACS_311;
Other reasons included simplification (17%), of which 40% were Triumeq to Dovato, virological failure (3%) and other...Bictegravir, raltegravir, darunavir and other antiretrovirals each accounted for 4%, and the associated drug was unknown in 1%...Efavirenz is still associated with the highest number of toxicity-related switches, however, switches from tenofovir have doubled, possibly due to the introduction of tenofovir alafenamide and two-drug regimens. The introduction of dolutegravir and doravirine has highlighted new toxicities.
- bictegravir (GS-9883) / Gilead
Bictegravir alters glucose tolerance and metabolism (MAZUREK) - Sep 10, 2023 - Abstract #EACS2023EACS_304;
The introduction of dolutegravir and doravirine has highlighted new toxicities. Purpose :
- Sunlenca (lenacapavir) / Gilead
Resistance analysis of long-acting lenacapavir in heavily treatment-experienced people with HIV after 104 weeks of treatment (POLONEZ) - Sep 10, 2023 - Abstract #EACS2023EACS_295;
Plasma concentrations of OBR (darunavir, tenofovir alafenamide, tenofovir, emtricitabine, dolutegravir) were quantified using a validated LCMS method. Conclusions :
- Tivicay (dolutegravir) / ViiV Healthcare
Change in blood pressure, weight and other cardiovascular disease risk factors after switch to dolutegravir versus staying on a protease inhibitor; post-hoc analysis of the 48-week randomised 2SD trial (ePosters area) - Sep 10, 2023 - Abstract #EACS2023EACS_259;
Predictors of incident hypertension included age, body mass index and creatinine clearance. Conclusions :
- bictegravir (GS-9883) / Gilead, Tivicay (dolutegravir) / ViiV Healthcare
Dolutegravir but not bictegravir exposure increases in vitro platelet aggregation (ETIUDA) - Sep 10, 2023 - Abstract #EACS2023EACS_232;
Further evaluation of platelet activation in vivo and in clinical settings is required to validate our findings. Ultimately, this work may lead to identifying drug regimens with a lower CVD risk, allowing personalised options when treating PLWH.
- Tivicay (dolutegravir) / ViiV Healthcare
Pregnancy and Neonatal Outcomes Following Prenatal Exposure to Dolutegravir: The DOLOMITE-EPPICC Study (MAZUREK) - Sep 10, 2023 - Abstract #EACS2023EACS_204;
Ultimately, this work may lead to identifying drug regimens with a lower CVD risk, allowing personalised options when treating PLWH. Conclusions :
- | bictegravir (GS-9883) / Gilead, Tivicay (dolutegravir) / ViiV Healthcare
Journal: Weight gain following switch to integrase inhibitors from non-nucleoside reverse transcriptase or protease inhibitors in people living with HIV in the United States: analyses of electronic medical records and prescription claims. (Pubmed Central) - Sep 7, 2023
Weight gain and related metabolic health of PLWH switching from NNRTI to DTG or BIC should be closely monitored by clinicians. Further research is needed to assess other metabolic outcomes in PLWH remaining on PI and those who switch from PI to INSTI.
- || Tivicay (dolutegravir) / ViiV Healthcare
Review, Journal: Metabolic implications and safety of dolutegravir use in pregnancy. (Pubmed Central) - Sep 7, 2023
Possible effects on folate status, energy metabolism, adipogenesis, and oxidative stress are considered. In many instances, insufficient data are available, pointing to the need for additional research in this important area of HIV treatment.
- | Retrospective data, Journal: Associations of modern initial antiretroviral therapy regimens with all-cause mortality in people living with HIV in resource-limited settings: a retrospective multicenter cohort study in China. (Pubmed Central) - Sep 7, 2023
Only the differences in all-cause mortality of PLHIV between the efavirenz group and the nevirapine group, the dolutegravir group and the nevirapine group, and the lopinavir group and the nevirapine group, were observed in China. After stratifying the cause of mortality, we found that the differences in mortality between initial ART regimens were mainly observed in AIDS-related mortality.
- | Journal: Effect of Integrase Strand Transfer Inhibitor Use on Time to HIV Viral Suppression before Delivery. (Pubmed Central) - Sep 7, 2023
Despite recommendations to prescribe INSTI in pregnancy for rapid viral suppression, we did not find a significant difference in time to viral suppression when pregnant individuals were taking non-INSTI ARVs. We did not find that one INSTI ARV was superior for viral suppression.
- Juluca (dolutegravir/rilpivirine) / ViiV Healthcare, J&J
Steady-state PK of Fixed Dose Dolutegravir+Rilpivirine in Hemodialysis (Hall B + C) - Sep 6, 2023 - Abstract #IDWeek2023IDWeek_3077;
- dolutegravir/lamivudine/tenofovir disoproxil fumarate / Cipla, Laurus Labs, Aurobindo, Viatris, Hetero, Macleods, Tivicay (dolutegravir) / ViiV Healthcare
Randomized-Controlled Trial Evaluating The Outcome Between Switching to Tenofovir Disoproxil Fumarate(TDF)/Lamivudine(3TC)/Dolutegravir(DTG) Versus Maintaining The Current NNRTI Or Boosted-PI-containing Regimen in PLWH in Thailand (Hall B + C) - Sep 6, 2023 - Abstract #IDWeek2023IDWeek_2987;
- Outcomes in Patients Receiving Long-Acting Cabotegravir-Rilpivirine in a Community, Infusion Center-Based Administration Model in Columbus, Ohio (Hall B + C) - Sep 6, 2023 - Abstract #IDWeek2023IDWeek_2984;
- Tivicay (dolutegravir) / ViiV Healthcare
Impact of Dolutegravir-based Regimen on Metabolic Syndrome and its Components in Adults with HIV in Care at Hospital Roosevelt in Guatemala City (Hall B + C) - Sep 6, 2023 - Abstract #IDWeek2023IDWeek_2976;
- Incidence and Predicting Factors of Opportunistic Infections after Initiation of Antiretroviral Therapy: A Retrospective Cohort Study (Hall B + C) - Sep 6, 2023 - Abstract #IDWeek2023IDWeek_2969;
- Determinants associated with weight gain among persons with HIV who switch to integrase strand transfer inhibitors (INSTI) (Hall B + C) - Sep 6, 2023 - Abstract #IDWeek2023IDWeek_2956;
- Incidence of Errors in an INSTI-Based Era: A Comparison of Error Rates Between Single Versus Multiple Tablet INSTI-Based Regimens in the Inpatient Setting (Hall B + C) - Sep 6, 2023 - Abstract #IDWeek2023IDWeek_2953;
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead, Tivicay (dolutegravir) / ViiV Healthcare
Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) Versus Dolutegravir (DTG)?Based 3-Drug Regimens in Adults With HIV Who Have Suboptimal Antiretroviral Adherence (Hall B + C) - Sep 6, 2023 - Abstract #IDWeek2023IDWeek_2951;
- "Association Between Integrase Inhibitor Plasma Concentrations and Body Weight Gain in Women Living with HIV" (252 AB) - Sep 6, 2023 - Abstract #IDWeek2023IDWeek_1818;
- Tesamorelin Reduces Visceral Adipose Tissue and Liver Fat in INSTI-Treated Persons with HIV (Hall B + C) - Sep 6, 2023 - Abstract #IDWeek2023IDWeek_811;
- Tivicay (dolutegravir) / ViiV Healthcare
Geographic differences in weight change on dolutegravir: a prospective cohort study (Hall B + C) - Sep 6, 2023 - Abstract #IDWeek2023IDWeek_810;
- | dolutegravir/lamivudine/tenofovir disoproxil fumarate / Cipla, Laurus Labs, Aurobindo, Viatris, Hetero, Macleods, Tivicay (dolutegravir) / ViiV Healthcare
Journal: A novel formulation enabled transformation of 3 HIV drugs tenofovir-lamivudine-dolutegravir (TLD) from short-acting to long-acting all-in-one injectable. (Pubmed Central) - Aug 31, 2023
This study confirms that TLD with disparate properties can be made stable by DcNP to enable TLD concentrations of 4?weeks in NHP. Study results highlighted the potential of TLD-in-DcNP as a convenient all-in-one, complete HIV long-acting product for clinical development.
- | Tivicay (dolutegravir) / ViiV Healthcare
Retrospective data, Journal: Retrospective longitudinal analysis of low-level viremia among HIV-1 infected adults on antiretroviral therapy in Kenya. (Pubmed Central) - Aug 31, 2023
Compared to patients who never received dolutegravir (DTG), patients who initiated DTG had lower risk of virologic non-suppression (aRR 0.60) and virologic failure (aRR 0.51); similarly, patients who transitioned to DTG had lower risk of virologic non-suppression (aRR 0.58) and virologic failure (aRR 0.35) for the same LLV range...No specific funding was received for the analysis. HIV program support was provided by the President's Emergency Plan for AIDS Relief (PEPFAR) through the United States Centers for Disease Control and Prevention (CDC).
- Tivicay (dolutegravir) / ViiV Healthcare
Tenofovir induced Lupus (e-Poster Hall) - Aug 30, 2023 - Abstract #EADV2023EADV_2380;
But antiretroviral therapy (ART) causing DILE is rarely described in literature. In this case though initially some of the features mimicked idiopathic lupus, the suspicion of ART as the causative agent helped to stop the offending drug which resulted in resolution of the DILE lesions and early management of this condition.
- | Tivicay (dolutegravir) / ViiV Healthcare
Journal, Patient reported outcomes: Improvements in patient-reported outcomes following initiation of dolutegravir- or low-dose efavirenz-based first-line antiretroviral therapy: A four-year longitudinal analysis in Cameroon (NAMSAL ANRS 12313 trial). (Pubmed Central) - Aug 29, 2023
In this case though initially some of the features mimicked idiopathic lupus, the suspicion of ART as the causative agent helped to stop the offending drug which resulted in resolution of the DILE lesions and early management of this condition. Although supporting the current WHO guidelines recommending DTG- and EFV400-based regimens as preferred and alternative first-line ART, further studies should investigate medium-term mental health outcomes in patients on DTG.
- ||| Tivicay (dolutegravir) / ViiV Healthcare, GSK3640254 / ViiV Healthcare
Trial completion, Combination therapy: DYNAMIC: A Clinical Trial of GSK3640254 + Dolutegravir (DTG) in Human Immunodeficiency Virus-1 Infected Treatment-naive Adults (clinicaltrials.gov) - Aug 29, 2023
P2b, N=85, Completed, Sponsor: ViiV Healthcare
Although supporting the current WHO guidelines recommending DTG- and EFV400-based regimens as preferred and alternative first-line ART, further studies should investigate medium-term mental health outcomes in patients on DTG. Active, not recruiting --> Completed
- | Tivicay (dolutegravir) / ViiV Healthcare
Journal: Virological Non-Suppression among Newly Diagnosed HIV-Positive Individuals on Dolutegravir-Based Antiretroviral Treatment in Eastern Ethiopia: Follow-Up Study. (Pubmed Central) - Aug 25, 2023
Thus, targeted interventions, the introduction of baseline VL testing to improve treatment outcomes, and fostering the attainment of UNAIDS 95-95-95 targets are recommended. Furthermore, broader research is recommended to explore the reasons for virological non-suppression in the study area.
- | Tivicay (dolutegravir) / ViiV Healthcare, Isentress (raltegravir) / Merck (MSD), Vitekta (elvitegravir) / Japan Tobacco, Gilead
Journal: Convenience, efficacy, safety, and durability of INSTI-based antiretroviral therapies: evidence from the Italian MaSTER cohort. (Pubmed Central) - Aug 23, 2023
Durability worked in favor of DTG which appeared to perform better in this cohort compared to RAL and EVG, though length of follow-up was significantly shorter for DTG. These observational results need to be confirmed in further perspective studies with longer follow-up.
- | Tivicay (dolutegravir) / ViiV Healthcare
Journal: Design, synthesis and antitumour activity evaluation of novel dolutegravir derivatives. (Pubmed Central) - Aug 23, 2023
In addition, compound 4g induced apoptosis and clonal suppression in A549 tumor cells. Compound 4g also activated the LC3 signaling pathway to induce autophagy in tumor cells, and activated the ?-H2AX signaling pathway to induce DNA damage in tumor cells.
- | Juluca (dolutegravir/rilpivirine) / ViiV Healthcare, J&J, Edurant (rilpivirine) / J&J, Tivicay (dolutegravir) / ViiV Healthcare
Journal: Therapeutic drug monitoring and virological response at week 48 in a cohort of HIV-1 infected-patients switching to dolutegravir/rilpivirine dual maintenance therapy (ANRS-MIE-BIRIDER Study). (Pubmed Central) - Aug 21, 2023
Compound 4g also activated the LC3 signaling pathway to induce autophagy in tumor cells, and activated the ?-H2AX signaling pathway to induce DNA damage in tumor cells. A majority of PLWHA receiving DTG/RPV maintenance dual therapy demonstrated VL<50 cp/mL but virological replication was more frequent in people living with HIV/AIDS with subtherapeutic Cmin.
- ||| Journal, Adverse events: META-INSTI: metabolic adverse events following integrase strand transfer inhibitor administration in spontaneous adverse event reports. (Pubmed Central) - Aug 21, 2023
ID Week. Virtual 2020.
- | Vemlidy (tenofovir alafenamide) / Gilead
Retrospective data, Journal: Young age is a key determinant of body weight gain after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in Japanese people living with HIV. (Pubmed Central) - Aug 21, 2023
In Japanese PLWH, annual body weight change was comparable in TDF- and TAF-period, while TAF plus DTG correlated with weight gain. Since young age was a key determinant of weight change, careful interpretation is needed for TAF-associated weight gain.
- | Tivicay (dolutegravir) / ViiV Healthcare
Journal, HEOR, Cost-effectiveness, Cost effectiveness: Cost-effectiveness of dolutegravir vs. efavirenz-based combined antiretroviral therapies in HIV-infected treatment-naive patients in a Nigerian treatment centre. (Pubmed Central) - Aug 11, 2023
Efavirenz based regimen had higher treatment effectiveness than DTG-based regimen in treatment-naive patients after initiating treatment in a short term. Compared to EFV, DTG-based regimen is cost-effective in the management of treatment na
- || Clinical, PK/PD data, Review: Pharmacokinetics of Antiretroviral Drugs in Older People Living with HIV: A Systematic Review. (Pubmed Central) - Aug 10, 2023
Exposure to DRV increases modestly with age, while exposure to BIC, DOR and RAL appears to be unaffected by age. As the available evidence to confirm a potential effect of aging on ARV pharmacokinetics is limited, further studies are necessary.
- | Tivicay (dolutegravir) / ViiV Healthcare
Trial initiation date: Pharmacokinetics and Safety of Double-dose Dolutegravir When Used With Rifapentine for HIV-associated Tuberculosis (clinicaltrials.gov) - Aug 9, 2023
P2, N=30, Not yet recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
As the available evidence to confirm a potential effect of aging on ARV pharmacokinetics is limited, further studies are necessary. Initiation date: May 2023 --> Oct 2023
- Tivicay (dolutegravir) / ViiV Healthcare
Trial completion date, Trial primary completion date: Drug-Drug Interactions Between Rifapentine and Dolutegravir in HIV/LTBI Co-Infected Individuals (clinicaltrials.gov) - Aug 9, 2023
P2, N=72, Suspended, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Initiation date: May 2023 --> Oct 2023 Trial completion date: Oct 2023 --> May 2025 | Trial primary completion date: Aug 2023 --> Feb 2025
- ||| Tivicay (dolutegravir) / ViiV Healthcare, Vitekta (elvitegravir) / Japan Tobacco, Gilead
Journal, Adverse events, Real-world evidence, Real-world: Neuropsychiatric Adverse Events Following Antiretroviral Therapy in People Living with HIV: A Real-World Study of Dynamic Trends and Risk Factors in Hangzhou, China. (Pubmed Central) - Aug 8, 2023
Treatment-induced changes in CD4-positive T-cell count and virological suppression did not depend on the particular choice of ART regimen. The prevalence of sleep disorders and anxiety changed significantly over time on ART and the risks of these disorders were associated with seven common clinical and
- ||| Tivicay (dolutegravir) / ViiV Healthcare
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: DOLUVOIR: Cartography of Virologic Reservoir Related to Antiretroviral Concentrations in HIV-1 Chronic Patients Treated by a First Line Treatment Containing Dolutegravir and Associated Nucleoside / Nucleotide Reverse Transcriptase Inhibitors Backbone (clinicaltrials.gov) - Aug 7, 2023
P=N/A, N=20, Completed, Sponsor: ANRS, Emerging Infectious Diseases
The prevalence of sleep disorders and anxiety changed significantly over time on ART and the risks of these disorders were associated with seven common clinical and Recruiting --> Completed | N=34 --> 20 | Trial completion date: Nov 2023 --> Jun 2023 | Trial primary completion date: Oct 2022 --> Jun 2023
- | Tivicay (dolutegravir) / ViiV Healthcare
Retrospective data, Journal: Effect of dolutegravir-based first-line antiretroviral therapy on weight and body mass index among adult people living with HIV on follow up at health facilities in Hawassa city administration, Southern Ethiopia: a retrospective cohort study. (Pubmed Central) - Aug 6, 2023
Initiating ART with TLD was significantly associated with greater weight and BMI gain than the NNRTI-based regimens. Therefore, the cardio-metabolic implications of weight gain after the TLD initiation in this population should be monitored and thoroughly investigated.
- | Tivicay (dolutegravir) / ViiV Healthcare, Vemlidy (tenofovir alafenamide) / Gilead
Journal: Tenofovir alafenamide plus dolutegravir as a switch strategy in HIV-infected patients: a pilot randomized controlled trial. (Pubmed Central) - Aug 4, 2023
Treatment simplification with tenofovir alafenamide plus dolutegravir regimen as maintenance therapy was non-inferior in terms of efficacy and safety compared to the standard triple therapy. Comparing efficacy of antiretroviral therapy.
- | Tivicay (dolutegravir) / ViiV Healthcare
Journal: Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir. (Pubmed Central) - Aug 4, 2023
Although most changes were favourable, adiponectin reduction was not. There were non-significant changes in CIMT progression.
- | Journal: Transmitted Drug Resistance Against Integrase Strand Transfer Inhibitors in Iranian HIV-Infected Na (Pubmed Central) - Aug 4, 2023
Based on the findings and compared to our previous study, all patients were sustainable to main integrase inhibitors, including bictegravir, raltegravir, bictegravir, elvitegravir and dolutegravir. It seems the resistant mutation pattern attributed to integrase inhibitors was not diffent among studied patients; hence, the prescription of such inhibitors helps physicians to control HIV infection in Iranian HIV-infected patients.
- HSV-1 PNEUMONIA IN AIDS PATIENT LEADING TO VENT DEPENDENCY (Convention Center Exhibit Hall) - Aug 4, 2023 - Abstract #CHEST2023CHEST_1181;
- | Tivicay (dolutegravir) / ViiV Healthcare
Journal: Associations of HIV and antiretroviral therapy with gestational diabetes: findings from a prospective cohort in South Africa. (Pubmed Central) - Aug 3, 2023
Among PHIV, GDM risk was similar regardless of EFV or DTG use. Given concerns about DTG and weight gain, diabetes risk should continue to be monitored.
- | Dovato (dolutegravir/lamivudine) / ViiV Healthcare
Enrollment open, Trial completion date, Trial primary completion date, Head-to-Head: D3 (Penta21): DTG/3TC Fixed Dose Formulations for the Maintenance of Virological Suppression in Children with HIV Infection Aged 2 to <15 Years Old (clinicaltrials.gov) - Aug 3, 2023
P2/3, N=370, Recruiting, Sponsor: PENTA Foundation
Given concerns about DTG and weight gain, diabetes risk should continue to be monitored. Not yet recruiting --> Recruiting | Trial completion date: Apr 2025 --> Sep 2025 | Trial primary completion date: Oct 2022 --> Oct 2023